Lymphatic Diseases clinical trials
The registry lists 83 studies for Lymphatic Diseases across more than 10 countries. 12 are recruiting or about to start. 12 of them are mainly about Lymphatic Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-04. Counting its 73 narrower conditions too, such as Multiple Myeloma: 16,419 studies, 3,670 open.
Get an email when these change. Save the Lymphatic Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Seagen Inc. (7) · UNC Lineberger Comprehensive Cancer Center (5) · Amgen Research (Munich) GmbH (5) · Newport Pharmaceuticals International (3) · Novartis Pharmaceuticals (2) · Nordic Nanovector (2) · Celgene (2) · Oncternal Therapeutics, Inc (2)
What is being tested here
Drugs under test in Lymphatic Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · Alkylating agents 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 7, phase 3 first
- Feb 2027A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) · Phase 3 · Acerta Pharma BV
- Dec 2026HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis · Center for International Blood and Marrow Transplant Research
- Dec 2026Lymphaticovenous Anastomosis as Treatment for Lymphedema · Odense University Hospital
- Dec 2026Early Screening Markers of Herpes Zoster Neuralgia · Tongji Hospital
- Jan 2027Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units · Masonic Cancer Center, University of Minnesota
- Jul 2027CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) · Curis, Inc.
- Sep 2027A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Who these studies take
Of the 9 Lymphatic Diseases studies recruiting now, 6 (67%) set no upper age limit and 0 (0%) stop at 75 or younger. 4 (44%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (22%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (44%) | 4 (44%) |
| 18 | 9 (100%) | 9 (100%) |
| 30 | 9 (100%) | 9 (100%) |
| 40 | 9 (100%) | 9 (100%) |
| 50 | 9 (100%) | 9 (100%) |
| 65 | 9 (100%) | 9 (100%) |
| 75 | 9 (100%) | 9 (100%) |
| 85 | 8 (89%) | 8 (89%) |
Across all 83 studies, recruiting or not: 22% stop at 75 or younger and 14% at 65; 19% take children; 2% are for women only and 5% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 83. Browse all 83 → or search them.
- A Prospective Natural History Study of Lymphatic AnomaliesRecruitingNCT057311411 country
- CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)RecruitingNCT03328078Phase 1/27 countries
- Infusion of Cell Populations From Unlicensed Umbilical Cord Blood UnitsRecruitingNCT01451502Not applicable1 country
- Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureRecruitingNCT06651970Phase 46 countries
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/27 countries
- Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO StudyEnrolling by invitationNCT049967061 country
- Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic DisordersEnrolling by invitationNCT008335991 country
- European Registry Study on Lymphatic InterventionsRecruitingNCT071312931 country
- Early Screening Markers of Herpes Zoster NeuralgiaNot yet recruitingNCT07038707
- ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-LymphomaRecruitingNCT04097067Not applicable1 country
- Radiological Changes of Glymphatic-meningeal Lymphatic Drainage System After Subarachnoid HemorrhageRecruitingNCT064444381 country
- International Lymphatic Disease and Lymphedema RegistryRecruitingNCT013367901 country
- Sepantronium Bromide for the Treatment of High-grade B-cell LymphomaCompletedNCT05263583Phase 22 countries
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 323 countries
- Administration of T Lymphocytes for Prevention of Relapse of LymphomasActive, not recruitingNCT02663297Phase 11 country
- DPX-Survivac and Checkpoint Inhibitor in DLBCLCompletedNCT03349450Phase 21 country
- GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALLTerminatedNCT04601584Phase 1/21 country
- HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 21 country
- Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell LymphomaActive, not recruitingNCT03696784Phase 11 country
- BV-CHEP Chemotherapy for Adult T-cell Leukemia or LymphomaCompletedNCT03264131Phase 21 country
- Prevalence of Chapman Reflex Points in Medical Students and Their Association With Visceral SymptomsCompletedNCT076911121 country
- Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHLActive, not recruitingNCT02690545Phase 1/21 country
- Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCLActive, not recruitingNCT03602157Phase 11 country
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/21 country
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 21 country
- Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.Active, not recruitingNCT051450621 country
- Lymphatic Phenotype in Noonan Syndrome Spectrum DisordersCompletedNCT06267807Not applicable1 country
- A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)CompletedNCT03744676Phase 21 country
- Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)CompletedNCT055295241 country
- Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's LymphomasTerminatedNCT04305444Phase 21 country
- A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell MalignanciesTerminatedNCT05588440Phase 1/21 country
- A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)TerminatedNCT03743246Phase 1/26 countries
- Lymphaticovenous Anastomosis as Treatment for LymphedemaActive, not recruitingNCT05441943Not applicable1 country
- Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)CompletedNCT02658968Phase 15 countries
- A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT02733042Phase 1/27 countries
- A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT05431179Phase 3
- Octreotide Improves Human Lymphatic Fluid Transport a Translational TrialCompletedNCT05683444Early Phase 11 country
- Effect of Peritoneal Fixation on Lymphocele FormationCompletedNCT04853095Not applicable1 country
- Sildenafil for the Treatment of Lymphatic MalformationsCompletedNCT02335242Phase 21 country
- A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT01667133Phase 1/21 country
- SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis FungoidesTerminatedNCT03713320Phase 28 countries
- Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL PatientsCompletedNCT02497131Phase 21 country
- Micro-mobile Foot Compression and Diabetic FootCompletedNCT03135535Phase 21 country
- Study Evaluating Venetoclax in Subjects With Hematological MalignanciesCompletedNCT02265731Phase 1/21 country
- Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher DiseaseCompletedNCT024166617 countries
- Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage SettingTerminatedNCT02499627Phase 21 country
- Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell TransplantNo longer availableNCT012000171 country
- A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01990534Phase 47 countries
- PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR StudyTerminatedNCT03837457Phase 23 countries
- The Effect of Manual Lymphatic DrainageCompletedNCT04461132Not applicable1 country